advanced search

EXPERT VIEW

ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?
EXPERT VIEW
Nigel Theobald
ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?
Nigel Theobald, discusses key issues and strategies for formulation scientists aiming to unlock the potential of oral delivery for small interfering ribonucleic acid drugs targeted against gastrointestinal diseases and cancers.
DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS
EXPERT VIEW
Mariona Venceslao Molins
DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS
Mariona Venceslao Molins and Liliana Miinea discuss how excipient-based approaches can facilitate patient-centric formulations and transform oral suspensions.
STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY
EXPERT VIEW
Dr Jnanadeva Bhat
STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY
Jnanadeva Bhat and Manali Dalvi discuss the factors contributing to gelatin cross-linking in oral solid dose delivery – and strategies to tackle the resulting challenges.
CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”
EXPERT VIEW
Dr Zdravka Misic
CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”
Zdravka Misic explores how formulation expertise can be applied to overcome the low bioavailability of cannabinoids and how innovation in orally disintegrating tablets is driving progress for cannabidiol-based therapeutics.
THROUGH THICK AND THIN: MODELLING THE DELIVERY OF NON-NEWTONIAN FORMULATIONS
EXPERT VIEW
Dr Alex Vasiev
THROUGH THICK AND THIN: MODELLING THE DELIVERY OF NON-NEWTONIAN FORMULATIONS
Alex Vasiev explores the challenges inherent in understanding flow rates in injectable drug delivery when dealing with non-Newtonian fluids, and provides an overview of how to calculate flow rates for power law, Carreau and Cross fluids.
ACCELERATING COMBINATION PRODUCT DEVELOPMENT USING DIGITAL TWIN TECHNOLOGY
EXPERT VIEW
Dan Cowen
ACCELERATING COMBINATION PRODUCT DEVELOPMENT USING DIGITAL TWIN TECHNOLOGY
Dan Cowen, Sebastian White and Anthony Robinson, discuss the value that implementing a digital twin could provide to drug delivery device design across multiple stages of a development programme.
SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES
EXPERT VIEW
Su Osorio
SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES
Su Osorio, Stephanie Mou and Charlie Dean, explore the delicate balance between patient and planet centricity and propose a user- and planet-centric approach for the development of sustainable medical devices.
NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS
EXPERT VIEW
Dr Timothy Noakes
NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS
Timothy Noakes, Sheryl Johnson and Richard Greenhough, discuss the status of the current move from high-global-warming-potential propellants for pressurised metered dose inhalers to more sustainable alternatives.
CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION
EXPERT VIEW
Pauline Janssen
CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION
Pauline Janssen, discusses the various available devices for pulmonary delivery of medications, with a deeper dive into the challenges presented by replacing pMDI propellants with high global warming potential with new alternatives, or whether the optimal solution could be phasing out pMDIs in favour of DPIs.
PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON
EXPERT VIEW
Catriona Eldridge
PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON
Catriona Eldridge, analyses whether the pharmaceutical industry is meeting its targets and doing enough in the fight against climate change.
REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY
EXPERT VIEW
Alastair Willoughby
REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY
Alastair Willoughby and Prem-Sagar Tank, explore various device trade-offs for both sustainability and cost in reusable injection devices, and consider how this compares with single-use devices. 
SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE
EXPERT VIEW
Matt Parker
SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE
Matt Parker, Simon Lyons and Alex Lyness, look at how the continued success of glucagon-like peptide-1 drugs is bringing into focus the need for environmentally sustainable self-injection systems. They discuss whether reloadable autoinjectors could be the way to boost sustainability, lower cost per dose, and match the scale and rate of adoption of these new therapies.
SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES
EXPERT VIEW
Dr Zaid Aqrawe
Merxin Ltd
SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES
Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
EXPERT VIEW
Dr Ethan Miller
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
Ethan Miller and Heather Jameson shed light on some of the intricacies that lipid-encapsulated therapeutics bring to the realm of inhalation therapies, and some considerations on how the type of inhalation device selected may help to mitigate issues around formulation stability and efficient delivery to target cells.
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
EXPERT VIEW
Dr Nia Stevens
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
Nia Stevens, discusses the potential benefits of developing vaccines for intranasal administration with a suitable drug delivery device, as well as the challenges associated with this delivery route.
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
EXPERT VIEW
Eric Kaneps
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
Eric Kaneps discusses the benefits of nasal drug delivery compared with other administration routes – and the challenges in R&D and clinical manufacturing.
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
EXPERT VIEW
Dr Carolina Dantas
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
Carolina Dantas and Ulf Krueger consider the challenges when it comes to the successful delivery of inhaled biological drugs.
DRUG DELIVERY TRENDS FOR 2024
EXPERT VIEW
Tom Oakley
Sanner Group
DRUG DELIVERY TRENDS FOR 2024
Tom Oakley and Kamaal de Silva consider how keeping abreast of the latest trends can help the industry predict and prepare for the future and, commenting from Springboard's privileged position at the centre of many of the drug delivery sector’s most exciting developments, discuss the top trends to look out for in 2024.
FROM CONCEPT TO CURE: MASTERING LIQUID SILICONE RUBBER FOR MEDICAL DEVICE DESIGN
EXPERT VIEW
Kamaal de Silva
FROM CONCEPT TO CURE: MASTERING LIQUID SILICONE RUBBER FOR MEDICAL DEVICE DESIGN
Kamaal de Silva discusses the potential value of liquid silicone rubber in medical device design, including how its processing differs from other elastomers and how the challenges involved in its design and implementation can be overcome with specialist knowledge and experience.
UNLOCKING THE POTENTIAL OF CONNECTED DRUG DELIVERY DEVICES FOR DIABETES
EXPERT VIEW
Paul Draper
UNLOCKING THE POTENTIAL OF CONNECTED DRUG DELIVERY DEVICES FOR DIABETES
Paul Draper discusses the current state of connected injection pens and devices in the diabetes space, exploring the benefits that connectivity can bring to drug delivery devices and considering how to exemplify good design in a connected injection device for diabetes drug therapies.
FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET
EXPERT VIEW
Ross Errington
FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET
Ross Errington explores how pharmaceutical companies can evolve their pMDI drug products to make them fit for the future considering the several recent regulatory changes that are transforming the landscape of inhalation drugs.
THE END OF THE ROAD FOR pMDIs?
EXPERT VIEW
Finn Heraghty
THE END OF THE ROAD FOR pMDIs?
Finn Heraghty and Heather Jameson explore the extent to which the healthcare needs of a population could be covered by the combined use of soft mist inhalers and dry powder inhalers, and discuss the factors that will impact the continued importance of pressurised metered dose inhalers going forward.
TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY
EXPERT VIEW
Dr Mark Allen
TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY
Mark Allen, Andrew Fiorini and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper. 
NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY
EXPERT VIEW
Dr Richard Johnson
NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY
Richard Johnson explores the changing nasal delivery landscape, highlighting challenges in nasal drug formulation and potential methods to overcome them.
Top